PharmaBlock Sciences (Nanjing), Inc. (300725.SZ) engages primarily in the research, development, production and sales of pharmaceutical molecular building blocks and related chemistry services; it offers a rationally designed collection of novel building blocks for drug discovery and development supplied from lab-scale to commercial volumes, building blocks-driven compound libraries, custom chemistry research services, contract development and manufacturing organization (CDMO) services for raw starting materials (RSMs), key intermediates, active pharmaceutical ingredients (APIs), drug substances and drug products including solid dosage forms and packaging, as well as low-carbon manufacturing technologies and regulatory support. Founded in 2008 and headquartered in Nanjing, Jiangsu Province, China, the company operates seven sites across China, the United States and Switzerland, including a major facility in the Greater Philadelphia area and a recently expanded R&D center in West Chester, Pennsylvania; it serves top global pharmaceutical companies, biotech firms and partners in the pharmaceutical R&D and commercial manufacturing sectors worldwide. Recent developments include the approval of a final cash dividend for A shares related to fiscal year 2024 payable in May 2025, ongoing expansion of GMP capabilities through its new U.S. R&D facility opened in 2023 to support increased project delivery, and recognition with the 2023 CMO Excellence in Green Chemistry Award alongside major peers, underscoring its strategic focus on sustainable, innovative chemistry processes.